Medical Clinic of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany.
In Vivo. 2011 Mar-Apr;25(2):185-9.
Therapeutic options for the treatment of malignant ascites are limited and could be broadened by immune-stimulatory drugs.
Soluble β-(1-3),(1-6)-D-glucan from Saccharomyces cerevisiae was administered i.p. into DBA/2-mice bearing the P388 lymphoma either freshly inoculated or as an established ascites-tumor. Its effect on survival, ascites volume and production of cytokines was examined.
The early, but not the later, administration of β-glucan showed a tendency to induce interleukin (IL)-12 in the ascites, whereas both treatment schedules demonstrated a clear tendency to reduce production of interferon-γ in the abdominal fluid and had no notable impact on the level of tumor necrosis factor-α. Treatment with β-glucan at either time-point showed no effect on the ascites volume and mean survival time.
β-(1-3), (1-6)-D-Glucan shows weak and differential modulation of immune-stimulatory and pro-inflammatory cytokines in tumor ascites dependent on the stage of tumor growth without affecting survival of the mice.
治疗恶性腹水的治疗选择有限，可以通过免疫刺激药物来拓宽。
酵母来源的可溶性β-(1-3)，(1-6)-D-葡聚糖通过腹腔内给药，给予患有 P388 淋巴瘤的 DBA/2 小鼠，无论是新接种的还是已建立的腹水肿瘤。检查其对生存、腹水体积和细胞因子产生的影响。
β-葡聚糖的早期（而非晚期）给药有诱导腹水白细胞介素（IL）-12 的趋势，而两种治疗方案均明显倾向于减少腹腔液中干扰素-γ的产生，对肿瘤坏死因子-α水平没有显著影响。在任何时间点用β-葡聚糖治疗均对腹水体积和平均生存时间没有影响。
β-(1-3)，(1-6)-D-葡聚糖在依赖于肿瘤生长阶段的肿瘤腹水中显示出对免疫刺激和促炎细胞因子的弱而不同的调节作用，而不影响小鼠的生存。
